Remove Bioinformatics Remove DNA Remove Virus
article thumbnail

Improving viral vector safety for gene therapies

Drug Discovery World

While many different modalities of delivery vectors exist, the two most common viral vectors are lentivirus and adeno-associated virus. Following initial viral vector transduction, treated samples, typically whole blood and/or enriched cell populations, are collected and the genomic DNA is isolated. The enriched DNA is then sequenced.

Therapies 147
article thumbnail

Guide to using AAV vectors in gene therapy

Drug Discovery World

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. Questions were fielded from the audience, which included: What analysis will be performed to evaluate host or other DNA contamination? Why are those important?

Therapies 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Start-up hopes to boost production of viral vectors for ATMPs

Drug Discovery World

The company’s DNA-based platform is being developed to address manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to produce advanced therapy medicinal products (ATMPs).

article thumbnail

Guide to using AAV vectors in gene therapy

Drug Discovery World

Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. Questions were fielded from the audience, which included: What analysis will be performed to evaluate host or other DNA contamination? Why are those important?

Therapies 130
article thumbnail

Drug discovery deals highlight key growth areas

Drug Discovery World

GenomeFrontier partners with BioCina on CAR-T therapy CDMO BioCina and GenomeFrontier Therapeutics will partner on the development of virus-free CAR-T products for cancer treatment. BioCina will provide process development and GMP manufacturing for Minicircle DNA and Plasmid DNA.

DNA 130
article thumbnail

Not all neoantigens are created equal

Drug Target Review

During the process of transformation from a normal cell into a cancer cell, a cell acquires a series of changes, or mutations, in its DNA. But DNA mutations can also result in changes to the proteins that are displayed on the surface of the cancer cell. These mutations are called clonal mutations or clonal neoantigens.

article thumbnail

Is That DNA Dangerous?

Codon

Tessa Alexanian and Max Langenkamp build computational DNA screening tools for a living. But today, rapid advances in DNA synthesis have made it possible for would-be bioterrorists to make pathogens, rather than buy them. government must order synthetic DNA from providers who publicly state that they follow the U.S.

DNA 85